tbuckley/cabot-search huggingface dataset:
Genome-wide copy number analysis of circulating tumor cells from patients (pts) with metastatic breast cancer (MBC).
Authors: M. J. M. Magbanua, E. Sosa, R. Roy, L. Eisenbud, J. Scott, A. Olshen, D. Pinkel, H. S. Rugo, J. W. Park
Journal: Journal of Clinical Oncology (2011)

9 Background: We developed a novel approach to isolate circulating tumor cells (CTCs) via immunomagnetic enrichment followed by fluorescence activated cell sorting (IE/FACS) and examined copy number alterations in these cells. Methods: Magnetic beads coated with EpCAM mAb were added to blood to enrich for tumor cells. Enriched samples were then subjected to FACS analysis using differentially labeled mAbs to distinguish tumor cells (EpCAM+) from leukocytes (CD45+) during sorting. DNA from isolated tumor cells was subjected to whole genome amplification (WGA) and copy number analysis via array comparative genomic hybridization (aCGH). The assay was evaluated in CTCs from 5 MBC pts with matched archival primary tumors and later extended to an additional 176 MBC pts, 97 of which were successfully profiled. Results: Comparison of CTCs with matched archival primary tumors confirmed shared lineage with notable divergence. In addition, serial testing of CTCs confirmed reproducibility, and indicated genomic change over time. Genomic profiling of CTCs from 102 MBC pts revealed a wide range of copy number alterations including those previously reported in breast cancer. Comparison with a published aCGH dataset of primary breast tumors revealed similar frequencies of recurrent genomic copy number aberrations. Conclusions: It is feasible to isolate CTCs away from hematopoietic cells with high purity via IE/FACS and profile them via aCGH analysis following WGA. Our approach may be utilized to explore genomic events involved in cancer progression and to monitor therapeutic efficacy of targeted therapies in clinical trials in a relatively non-invasive manner. This work was supported by grants from the CALGB, BCRF, TBCRC (Avon, Komen), EDRN and U54.
Histological Assessment of Cutaneous Acute Graft-Versus-Host Disease in a Preclinical Swine Model of Hematopoietic Cell Transplantation and Vascularized Skin Flap Tolerance
Authors: George F. Murphy, Raimon Duran-Struuck, Evan A. Farkash, Mihail Climov, David A. Leonard, Curtis L. Cetrulo, Thomas R. Spitzer, David H. Sachs, Christene A. Huang
Journal: Blood (2012)
Alterations of Plasma Complement C3b, C5b and VWF, ADAMTS13 in Patients with Graft-Versus-Host Disease and Thrombotic Microangiopathy after Hematopoietic Stem-Cell Transplantation
Authors: Yue Han, Jie Wang, Jia Chen, Jiaqian Qi, Jian Su, Zhenni Ma, Yaqiong Tang, Wei Han, Aining Sun, Zhaoyue Wang, Changgeng Ruan, Wu Depei
Journal: Blood (2015)
Abstract 6002: Biodegradable-polymer Infinnium Paclitaxel-eluting And Supralimus Sirolimus-eluting Stents Reduce Neointimal Proliferation In Patients At Low Risk Of Restenosis: Findings From The 3-arm Paint Randomized Controlled Trial
Authors: Pedro A Lemos, Bruno Moulin, Marco A Perin, Ludmilla A de Oliveira, J. Airton de Arruda, Valter C de Lima, Antonio A Lima, Ricardo Lasevitch, Cesar R Medeiros, Mauricio R Barbosa, Fabio S de Brito, Expedito E Ribeiro, Paulo R Caramori
Journal: Circulation (2008)
Effect of everolimus therapy on skeletal muscle wasting in patients with metastatic renal cell carcinoma (mRCC): Results from a placebo-controlled study.
Authors: L. Albiges, S. Antoun, L. Martin, M. Merad, Y. Loriot, V. Baracos, B. J. Escudier
Journal: Journal of Clinical Oncology (2011)

319 Background: We have previously reported that sorafenib induces muscle wasting in mRCC (Antoun, JCO 2010). As everolimus exerts its antineoplastic through inhibition of the mammalian target of rapamycin (mTOR), a key element of intracellular signalling of protein synthesis in skeletal muscle, we hypothesized that muscle wasting would be also an important side effect of everolimus therapy. Methods: All patients with mRCC enrolled in RECORD 1 (everolimus (E) or placebo (P) post TKI failure) in IGR (n=40) were analyzed for this study. Patients were eligible if at least 2 CT scans were available. CT image analysis, which has high precision and specificity for evaluation of specific muscles, was used to define change in total skeletal muscle. The third lumbar vertebra (L3) was chosen as a landmark. Images were analyzed using Slice-O-Matic software V4.3 (Tomovision). Tissue Hounsfield unit thresholds were employed: −29 to +150 for skeletal muscle. Subsequently, tissue cross-sectional areas (cm 2 ) were computed. Results: 35 patients (83% male, median age 60y) were evaluable, 10 on P and 25 on E. In addition, 9 patients initially on P could cross to E (as per protocol) and were analyzed both on P and on E. Median durations of treatment were 79 and 263 days respectively on P and E. Placebo patients had stable body weight, with no significant mean gain or loss of muscle. By contrast, patients on E lost body weight over time: −2.5±3.6 kg by 83 d (p=0.02), −4.9±5.7 (p=0.005) by 167 d and –5.0±7.6 kg (p=0.02) by 286 d. E patients progressively lost skeletal muscle compared .with baseline from −2.5±5.9% at 83d (p=0.06), to −4.0±7.5% at 167d (p=0.03) and −4.8±6.8% at 263d (p=0.01). Interstingly, the 9 patients who had maintained body weight (+2.0 kg) and muscle (+2.7%) whilst on placebo, and crossed to E, promptly lost weight (−4.8 kg, p&lt;0.03) and skeletal muscle (−5.3%) (about 1.5 kg of muscle) when crossed to E. Conclusions: Body weight and muscle wasting are induced by everolimus in mRCC, and are not related to progressive disease. These changes increase over time. Relation between these changes and outcome will be presented at the meeting. [Table: see text]
Cost-effectiveness of Prophylactic Moisturization for Atopic Dermatitis
Authors: Shuai Xu, Supriya Immaneni, Gordon B. Hazen, Jonathan I. Silverberg, Amy S. Paller, Peter A. Lio
Journal: JAMA Pediatrics (2016)

Emerging evidence suggests that the use of moisturizers on newborns and infants (ie, from birth to 6 months of age) is potentially helpful in preventing the development of atopic dermatitis.To investigate the cost-effectiveness of using a daily moisturizer as prevention against atopic dermatitis among high-risk newborns.In a cost-effectiveness analysis, the average cost of total-body moisturization using 7 common moisturizers from birth to 6 months of age was determined for male and female infants. We assumed the same unit of weight per moisturizer used for a given body surface area. Based on previously reported data (relative risk reduction of 50%), the incremental gain in quality-adjusted life-years (QALYs) was determined using a 6-month time window. The cost-effectiveness of each moisturizer was determined by assuming equal efficacy. A sensitivity analysis was conducted by varying the relative risk from 0.28 to 0.90.Use of prophylactic moisturizing compounds.The primary outcomes were the incremental cost-effectiveness values ($/QALY) for each moisturizer in preventing atopic dermatitis during a 6-month time window.The calculated amount of daily all-body moisturizer needed at birth was 3.6 g (0.12 oz) per application, which increased to 6.6 g (0.22 oz) at 6 months of age. Of the 7 products evaluated, the average price was $1.07/oz (range, $0.13/oz-$2.96/oz). For a 6-month time window, the average incremental QALY benefit was 0.021. The sensitivity analysis showed that the incremental gain of QALY ranged from 0.0041 to 0.030. Petrolatum was the most cost-effective ($353/QALY [95% CI, $244-$1769/QALY) moisturizer in the cohort. Even assuming the lowest incremental QALYs for the most expensive moisturizer, the intervention was still less than $45 000/QALY.Overall, atopic dermatitis represents a major health expenditure and has been associated with multiple comorbidities. Daily moisturization may represent a cost-effective, preventative strategy to reduce the burden of atopic dermatitis.
Elevated Expression of CKS1B at 1q21 Is Highly Correlated with Short Survival in Myeloma.
Authors: Fenghuang Zhan, Jeffrey Sawyer, Sushil Gupta, Yongsheng Huang, Elias Anaissie, Hongwei Xu, Ichior Hanamura, Madhumita Santra, Maurizio Zangari, Choon-kee Lee, Athanasios Fassas, Frits van Rhee, Klaus Hollmig, Giampaolo Talamo, Raymond Thertulian, Guido Tricot, William Barlow, Erik Rasmussen, John Crowley, Bart Barlogie, Shaughnessy John
Journal: Blood (2004)
Phase I/II trial of concurrent sunitinib (SU) and image-guided radiotherapy (IGRT) followed by maintenance systemic therapy for patients with oligometastases.
Authors: J. Kao, J. A. Cesaretti, M. W. Sung, R. Stock, M. D. Galsky, S. Packer, S. Chen
Journal: Journal of Clinical Oncology (2011)

306 Background: Preclinical data suggest that SU enhances the efficacy of radiotherapy. We tested the combination of SU and hypofractionated IGRT in a cohort of patients with historically incurable distant metastases. Methods: Eligible patients had 1 to 5 sites of metastatic solid tumors measuring ≤ 6 cm. The most common tumor types treated were head and neck, liver, lung, kidney, and prostate cancers. Patients were treated with concurrent SU (25 to 50 qd d 1–28) and IGRT (40 to 50 Gy in 10 fractions d 8–19). Following IGRT, patients could either receive maintenance SU (50 mg daily, 4 weeks on/2 weeks off starting on d 43) or alternate forms of systemic therapy. Most patients were treated with the recommended phase II dose of SU 37.5 mg and IGRT 50 Gy. Maintenance SU was used in 40% of patients. Results: Between 2/07 and 6/08, 43 patients with 81 metastatic lesions were enrolled with a median follow up for surviving patients was 20.1 months (range, 5–37 months). The incidence of acute grade ≥ 3 toxicities was 33%, most commonly myelosuppression, bleeding and abnormal liver function tests. The 2-year estimates for local control and distant control were 74% and 43%, respectively. The 2-year estimates for progression- free survival and overall survival were 39% and 46%, respectively. To date, 15 (35%) patients were alive without evidence of disease, 6 (14%) were alive with distant metastases, 13 (30%) were dead from distant metastases, 1 (2%) was dead from local progression, 6 (14%) were dead from comorbid illness, and 2 (5%) were dead from treatment-related toxicities. Predictors of improved progression-free survival were genitourinary primary tumor (HR 0.18; p=0.04), IGRT dose &gt; 40 Gy (HR 0.21; p=0.005), number of metastases (HR 2.22; p=0.006) and maintenance SU (HR 0.31; p=0.06). Flow cytometry demonstrates a significant reduction in immune suppressive myeloid derived suppressor cells and T regulatory cells in SU treated patients. Conclusions: Concurrent SU and IGRT achieves durable local and distant control in a significant subset of patients with oligometastases, particularly patients with genitourinary primary tumors with ≤ 2 distant metastases. [Table: see text]
Association of local therapy in metastatic breast cancer and survival.
Authors: A. Sofi, I. Mohamed, M. Koumaya
Journal: Journal of Clinical Oncology (2011)

e11535 Background: Patients presenting with metastatic breast cancer (MBC) are usually offered systemic chemotherapy to control metastatic tumor burden and palliative radiation therapy to manage the symptomatic primary tumor. However there are reports of improved survival in patients with MBC who had better control of primary tumor. The aim of this study is to assess the impact of local therapy on the overall outcome of patients with MBC. Methods: After approval from the Ethics Committee, medical records of all patients with MBC that presented to our institution between 2000 and 2009 were reviewed. Based on the treatment received, patients were grouped as follows: Group-I- patients that underwent surgery and also received radiotherapy and chemo-/hormonal therapy; Group-II -patients that received radiotherapy and chemo-/hormonal therapy; and Group-III -patients that received chemo-/hormonal therapy alone. Data collected on all patients included demographics, tumor grade, metastatic sites and duration until last follow up or death. Kaplan Meier survival analysis and Cox proportional hazard regression were performed. Results: Of the 37 patients included in the study, 10 patients were in group-I, 17 patients in group-II and 10 patients in group-III. About 38% had high to anaplastic tumor grade and 48% had two or more metastatic sites in the body. Overall, the average survival time was 3.13 years (range: 0 to 17). A significant difference in survival estimates was noted between Group-I, II, and III with mean survival times of 8.83, 4.9, and 2.26 years respectively (Log Rank χ2=10.44, p=0.005). In age-adjusted multivariate Cox regression model (χ2=21.729, p=0.001), high/anaplastic tumor grade (p=0.036), African-American race (p=0.009), CNS metastasis (p=0.003), Group-II (p=0.006), and Group III (p=0.002) were associated with poor survival. Survival was not associated with estrogen and progesterone receptor (ER/PR), and visceral or bone metastases. Conclusions: Aggressive local control of primary tumor in patients presenting with stage IV breast cancer is associated with improved survival.
Incidence of peritoneal carcinomatosis in recurrent plasmacytoid urothelial carcinomas (PUC) of the bladder: A retrospective analysis of patient outcomes at M. D. Anderson Cancer Center (MDACC).
Authors: Farshid Dayyani, Mark F. Munsell, Arlene O. Siefker-Radtke
Journal: Journal of Clinical Oncology (2012)

297 Background: PUC are a rare subset of urothelial cancers with a paucity of available literature regarding their clinical behavior. Methods: Retrospective analysis of outcomes among all patients (pts) with predominant PUC (pPUC) seen at MDACC from 1999-2010. Results: 31 pts with pPUC histology were identified (median age:63.5yrs; 83.3% male; TNM stage:cT1N0,n=4;cT2N0,n=8;cT3b-4aN0,n=6; cT4b, N+ or M+ n = 13). Median survival for all pts was 17.7mo (Stage I-III vs IV: 38.1 vs 13.3mo). Of 18 pts with potentially surgically resectable PUC (&lt;=pT4aN0M0) 7 received neoadjuvant chemotherapy,10 had initial surgery, and one was treated with TURBT alone. Despite pathologic downstaging in 67% of pts treated with neoadjuvant chemotherapy relapses were common and there was no difference in survival between pts treated with neoadjuvant chemotherapy compared to initial surgery, even though adjuvant chemotherapy was given in 7 patients. Only 1 pt in pCR remains in remission &gt;18 mo after surgery. The most common site of recurrence was in the peritoneum (13/18pts), with relapses occurring even in those with pCR at surgery. At least 4 pts developed CNS involvement with lepto-meningeal disease. In pts presenting with metastatic disease who were treated with chemotherapy, the median survival was 12.6 months. Conclusions: Plasmacytoid bladder tumors are a very aggressive subset with overall poor outcomes. Though chemotherapy sensitive with downstaging seen with neoadjuvant chemotherapy, there are few long-term survivors. There is a strong predilection for recurrences along the peritoneal lining, and peritoneal carcinomatosis should remain high on a clinician’s differential when patients develop obstructive bowel symptoms.
Efficacy of biologic agents (BA) in metastatic, triple-negative breast cancer (TNBC): A systematic review.
Authors: N. M. La Verde, A. Bramati, A. Bianchi, E. Galfrascoli, P. Sburlati, M. C. Garassino, S. Piva, V. Torri, M. Cinquini, G. Farina
Journal: Journal of Clinical Oncology (2011)

e11587 Background: TNBC accounts for about 15% of all invasive breast cancers, usually with an aggressive behavior and poor prognosis also because of lack of standard-of-care therapy. In this setting, BA in combination with chemotherapy (CT) may have a role, also based on TNBC cellular specific targets. Methods: To assess the role of BA in metastatic TNBC, a systematic review of randomized controlled trials published from January 2006 to January 2011 and of communications presented at ESMO, ASCO and SABCS congresses in 2009 and 2010 was performed. Only studies comparing BA+CT versus CT alone in TNBC, or in unspecified advanced breast cancer but presenting data on TNBC subgroup, were considered. The relevant statistical variables for the pooled analysis were the log of hazard ratio (HR) and relative variance for progression-free survival (PFS) and overall survival (OS). Results: Out of 346 Pubmed publications and 126 studies registered on http://clinicaltrial.gov, 8 trials were selected for analysis. A total of 3463 patients were analyzed: 1286 of them were TNBC patients. BA studied were: bevacizumab (Miles 2010, Brufsky 2010 and Gray 2009), lapatinib (Finn 2009), iniparib (O'Shaughnessy 2011), sunitinib (Curigliano 2010), sorafenib (Gomez 2010) and cetuximab (Baselga 2010). A PFS improvement was detected in the group of pts receiving BA, with a relative risk reduction of 27% (95% CI: 18%-35%). I2 statistic for quantifying heterogeneity among class of BA [1) anti-angiogenic, 2) EGFR inhibitors 3) Parp Inhibitors] was 43.8%; only class 1 and 3 showed a statistically significant improvement in PFS. No effect on OS was observed. Conclusions: In our systematic review we detected: 1. Improvement of PFS in TNBC pts treated with BA+CT vs CT alone. 2. No single BA class showed a statistically significant superiority over others, however for EGFR inhibitors no statistically significant difference was reached. 3. The effect of BA on OS hasn't been demonstrated, similarly in the general population with non-TNBC advanced breast cancer.
RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Intermediate Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO &amp; SFGM-TC French intergroup)
Authors: Olivier Tournilhac, Magali Le Garff-Tavernier, Reza Tabrizi, Stephanie Nguyen quoc, Faize Legrand-Izadifar, Patrice Chevallier, Oumedaly Reman, Cecile Tomowiak, Cecile Borel, Sylvie Francois, Pascal Turlure, Sébastien Maury, Gaelle Guillerm, Luc Fornecker, Richard Lemal, Claire Quiney, Carole Bellanger, Laure Calvet, Lauren Veronese, Aurelie Cabrespine, Mathieu Coudert, Jacques-Olivier Bay, Helene Merle-Beral, Nathalie Dhedin
Journal: Blood (2015)
Acquired Mutations in the BCR-ABL Kinase Domain in Imatinib Resistant Patients. Multicentric Experience in Argentina and Uruguay.
Authors: Patricia Gargallo, Beatriz Moiraghi, Eduardo Bullorsky, Rosa Santarelli, Maria Riva, Alicia Magarino, Ricardo Giuliani, Michele Bianchini, Jorge Milone, Ester Rosenfeld, Santiago Pavlovsky, Emilio Lanari, Adriana Arizo, Celina Avila, Castro R. Miguel, Rafael Conti, Fernanda Alu, Paula Barreyro, Rosario Custidiano, Roberto Bitton, Irene Larripa, Raquel Bengio
Journal: Blood (2006)
Comprehension and preferences for graphical representations of quality of life after prostate cancer treatment.
Authors: John L. Gore, Jason Izard, Daniel I. Avery, Cheryl Shih, Andrea Hartzler
Journal: Journal of Clinical Oncology (2012)

76 Background: Integration of quality of life (QoL) measurement into clinical prostate cancer (PCa) practice may enhance patients’ communication with clinicians, improve satisfaction with care, and affect the delivery of secondary therapies. A necessary step to achieve these benefits is illustrating QoL in ways patients can understand and use. Through a patient-partnered project, we developed graphical representations of prostate cancer QoL (dashboards) and compared patients’ comprehension and preferences among four alternative formats: table, bar chart, line graph, and pictograph. Methods: We conducted interviews with PCa patients and assessed health literacy, subjective numeracy, and graphic literacy with validated instruments (REALM, Subjective Numeracy Scale, Graphic Literacy Scale). We then presented patients the 4 candidate dashboards counterbalanced for format order, and assessed participants’ comprehension, helpfulness rating, and rank order preferences. Results: Our study included 29 PCa patients, with mean age 71 years (range 53-90). Patients were mostly white (86%) and had at least a college degree (76%). Most had localized PCa (90%) and 55% were treated within the last 5 years; 9 patients had undergone more than one type of treatment. Patients’ health literacy (mean score 6.9±0.26 out of 7), numeracy (mean score 4.3±0.94 out of 6), and graphic literacy (mean score 11.4±1.4 out of 13) was high. Comprehension did not vary by dashboard format (p=0.39), ranging from 84% correct for line graph to 91% correct for bar chart. The pictograph exhibited lower helpfulness ratings (p=0.001). Preference elicitation strongly favored the bar chart (p=0.004), ranked 1st by 52% of patients, and disfavored pictograph, ranked 4th by 69% of patients. Conclusions: Among a high literacy and numeracy sample of PCa patients, comprehension and preference ranking strongly favored bar charts for QoL dashboards. Pictographs, known to benefit low literacy patients, were not preferred despite good comprehension. Inclusion of lower literacy patients may yield different results. Future work will determine if clinical integration of QoL dashboards is associated with improved health outcomes.
Conditional Expression of a Leukemogenic Fusion Oncogene in Murine Hematopoietic Stem Cells Results in Highly Invasive AML with Origin-Related Genetic Signatures of Prognostic Significance for the Human Disease
Authors: Vaia Stavropoulou, Susanne Kaspar, Laurent Brault, Sabine Juge, Alexander Tzankov, Mathijs A. Sanders, Michael Kyba, Peter J.M. Valk, Antoine H.F.M. Peters, Juerg Schwaller
Journal: Blood (2014)
Discussion of Reports on Renal Factors in Hypertension
Journal: Circulation (1958)

The continuous secretion of renin by the chronically ischemic kidney was held to be unlikely in view of the experiments quoted by Dr. Kolff in which a rapid in situ transfer of an ischemic kidney to a normal dog did not raise the recipient's blood pressure. Measurable renin release was viewed rather as an acute intermittent response to a temporary reduction of renal circulation. Evidence from the classic experiment of Fasciolo, in which the transplanted chronic ischemic kidney caused hypertension in the recipient, was interpreted as showing the result of acute reduction in blood flow in the transplanted organ, rather than the chronic overproduction of renin. The depressor effect of antirenin injections in chronic renal hypertension might result from inhibition of the effect of renin on the hypothetical blood pressure regulating function of the normal kidney (Drs. Blaquier, Braun-Menéndez, Kolff). The magnitude of pressor response to injected renin and angiotonin was discussed by Drs. Langford, Wakerlin and Helmer. The pulmonary hypertension produced by renin and angiotonin and the lack of an elevation in pulmonary blood pressure in experimental renal hypertensin was discussed by Drs. Langford, Wakerlin, Sancetta, Braun-Menéndez and Stamler. Experiments disproving the importance of pulsatile flow as a stimulus to renin release were quoted by Dr. Kolff. An increase in the amount of the enzyme converting hypertensin I to its active form was considered as a possible mechanism for the production of hypertension by Drs. Leonard, Skeggs and Helmer. The relative importance of pressure per se and of renal insufficiency in the production of the necrotizing vascular lesion of malignant hypertension was discussed by Drs. Robert and Goldblatt.